88 related articles for article (PubMed ID: 38542097)
1. Targeting PIM Kinases to Improve the Efficacy of Immunotherapy.
Clements AN; Warfel NA
Cells; 2022 Nov; 11(22):. PubMed ID: 36429128
[TBL] [Abstract][Full Text] [Related]
2. PIM Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides.
Assirelli E; Ciaffi J; Scorcu V; Naldi S; Brusi V; Mancarella L; Lisi L; Pignatti F; Ursini F; Neri S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542097
[TBL] [Abstract][Full Text] [Related]
3. Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.
Maney NJ; Lemos H; Barron-Millar B; Carey C; Herron I; Anderson AE; Mellor AL; Isaacs JD; Pratt AG
Arthritis Rheumatol; 2021 Oct; 73(10):1820-1830. PubMed ID: 33779060
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
5. Is the C-reactive protein-to-albumin ratio the most remarkable simple inflammatory marker showing active disease in patients with axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis?
Kaplan H; Cengiz G; Şaş S; Eldemir YÖ
Clin Rheumatol; 2023 Nov; 42(11):2959-2969. PubMed ID: 37470884
[TBL] [Abstract][Full Text] [Related]
6. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
7. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
8. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
Chen S; Yang Y; Yuan Y; Bo Liu
Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
[TBL] [Abstract][Full Text] [Related]
9. PIM kinases regulate early human Th17 cell differentiation.
Buchacher T; Shetty A; Koskela SA; Smolander J; Kaukonen R; Sousa AGG; Junttila S; Laiho A; Rundquist O; Lönnberg T; Marson A; Rasool O; Elo LL; Lahesmaa R
Cell Rep; 2023 Dec; 42(12):113469. PubMed ID: 38039135
[TBL] [Abstract][Full Text] [Related]
10. Building a rheumatology biobank for reliable basic/translational research and precision medicine.
Assirelli E; Naldi S; Brusi V; Ciaffi J; Lisi L; Mancarella L; Pignatti F; Pulsatelli L; Faldini C; Ursini F; Neri S
Front Med (Lausanne); 2023; 10():1228874. PubMed ID: 37746090
[TBL] [Abstract][Full Text] [Related]
11. The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events.
Favalli EG; Cincinelli G; Germinario S; Di Taranto R; Orsini F; Maioli G; Biggioggero M; Ferrito M; Caporali R
Front Immunol; 2023; 14():1225160. PubMed ID: 37720218
[TBL] [Abstract][Full Text] [Related]
12. Pim1 promotes IFN-β production by interacting with IRF3.
Ko R; Seo J; Park H; Lee N; Lee SY
Exp Mol Med; 2022 Nov; 54(11):2092-2103. PubMed ID: 36446848
[TBL] [Abstract][Full Text] [Related]
13. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
